Selection of treatment for patients with early stage non-small cell Lung cancer in a multidisciplinary thoracic oncology program

Abstract

Lung cancer is the leading cause of cancer mortality in men and women. More than 170,000 Americans receive a diagnosis of lung cancer annually and the majority of them die of the disease [1]. There is considerable interest in improving treatment for lung cancer given its high impact on society. More than 80% of patients with lung cancer have non-small cell carcinoma (NSCLC). Surgery is the mainstay of treatment for patients with early stage NSCLC and results in cure of about 60-80% of patients with stage I (T1-2N0) disease [2]-[5]. © 2007 Springer-Verlag Berlin Heidelberg.